Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Lorenzo Spaggiari, Marina Chiara Garassino, Filippo de Marinis, Roberto Ferrara, Giulia Marvaso, Barbara Alicja Jereczek-Fossa, Gaia Piperno, Giuseppe Lo Russo, Giulia Corrao, Roberto Orecchia, Simone Giovanni Gugliandolo
Publikováno v:
Lung Cancer. 142:70-79
Presence of liver metastases correlates with worse survival and response to any treatments. This may be due to the microenvironment of liver which leads tumor to escape from Immune System. Stereotactic Body Radiation Therapy may help to sensitize Imm
Autor:
Elena Guerini-Rocco, Valeria Stati, Davide Radice, Filippo de Marinis, Ester Del Signore, Antonio Passaro, Letizia Gianoncelli, Chiara Catania, Caterina Fumagalli, Massimo Barberis, Gianluca Spitaleri
Publikováno v:
Anticancer Research. 40:427-433
BACKGROUND/AIM The role of anti-PD1/PD-L1 therapy (IO) in NSCLC harboring driver mutations is questionable. This study aimed to examine the efficacy of IO in patients with non-small cell lung cancer (NSCLC) with a KRAS mutation (KRAS+). PATIENTS AND
Autor:
Filippo de Marinis, Antonio Passaro
Publikováno v:
Translational Lung Cancer Research. 8:S334-S338
The precision medicine era in non-small cell lung cancer (NSCLC) was born with the identification of EGFR mutations and the possibility to treat patients harbouring EGFR alterations with specific and targeted tyrosine kinase inhibitors (1-3). Thinkin
Autor:
Filippo de Marinis, Helano C. Freitas, Yi-Long Wu, David Vicente, Gee-Chen Chang, Mariano Provencio, Nicolaas A. Bakker, J. Rigas, Sang We Kim, Qing Zhou, Liyan Jiang, Parneet Cheema, Gilberto de Castro, Claudio Martin, Giulio Metro, Byoung Chul Cho, Miguel F. Miranda, Johan Vansteenkiste, Yuh Min Chen
Publikováno v:
Future Oncology. 15:3003-3014
Aim: Osimertinib is a third-generation, irreversible, oral EGFR tyrosine kinase inhibitor. We report real-world effectiveness and safety data. Patients & methods: EGFR T790M positive advanced non-small-cell lung cancer adults, who received ≥1 prior
Autor:
Filippo de Marinis, Fiona H Blackhall, Martin Früh, Dirk De Ruysscher, Cecila Le Pechoux, Mary O’ Brien, Enriqueta Felip, Silvia Novello, Sara Ramella, Paul Martin Putora, Markus Glatzer, Rafal Dziadziuszko, L. Arés, José Belderbos, Fiona McDonald, Christoph Pöttgen, Esther G.C. Troost, Ursula Nestle, Benjamin Besse, Martin Reck, Federico Cappuzzo, Joachim Widder, Raffaele Califano, Paul Van Houtte, Françoise Mornex, Virginie Westeel, Pilar Garrido, Ben J. Slotman, Stéphanie Peeters, Corinne Faivre-Finn
Publikováno v:
Putora, P M, Glatzer, M, Belderbos, J, Besse, B, Blackhall, F, Califano, R, Cappuzzo, F, de Marinis, F, Dziadziuszko, R, Felip, E, Faivre-Finn, C, Früh, M, Garrido, P, le Pechoux, C, McDonald, F, Nestle, U, Novello, S, O‘Brien, M, Paz Ares, L, Peeters, S, Pöttgen, C, Ramella, S, Reck, M, Slotman, B, Troost, E G C, van Houtte, P, Westeel, V, Widder, J, Mornex, F & de Ruysscher, D 2019, ' Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts ', Radiotherapy and Oncology, vol. 133, pp. 163-166 . https://doi.org/10.1016/j.radonc.2018.12.014
Radiotherapy and Oncology, 133, 163-166. Elsevier Ireland Ltd
Radiotherapy and Oncology, 133, 163-166. Elsevier Ireland Ltd
Background: Due to conflicting results between major trials the role of prophylactic cranial irradiation (PCI) in stage IV small cell lung cancer (SCLC) is controversial.Methods: We obtained a list of 13 European experts from both the European Societ
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: Since the concept of oligometastatic (OM) disease was introduced in the oncological scenario of non-small cell lung cancer (NSCLC), these patients progressively became a new category of stage IV NSCLC in whom the multimodality approach, i
Autor:
Ester Del Signore, Francesco Petrella, Filippo de Marinis, Patrick Maisonneuve, Monica Casiraghi, Lorenzo Spaggiari, Giulia Sedda, Gaia Piperno
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 152
Objective Since data from large retrospective observational studies and cancer registries became available, suggesting a benefit for patients undergoing surgery, the role of surgery in the treatment of small cell lung cancer (SCLC) needs to be recons
Autor:
Juliana Guarize, Elena Guerini Rocco, Filippo de Marinis, Giulia Sedda, Luca Bertolaccini, Stefano Maria Donghi, Monica Casiraghi, Clementina Di Tonno, Massimo Barberis, Lorenzo Spaggiari
Publikováno v:
Jornal Brasileiro de Pneumologia
Jornal Brasileiro de Pneumologia, Vol 47, Iss 4 (2021)
Jornal Brasileiro de Pneumologia v.47 n.4 2021
Sociedade Brasileira de Pneumologia e Tisiologia (SBPT)
instacron:SBPT
Jornal Brasileiro de Pneumologia, Vol 47, Iss 4 (2021)
Jornal Brasileiro de Pneumologia v.47 n.4 2021
Sociedade Brasileira de Pneumologia e Tisiologia (SBPT)
instacron:SBPT
Objective: EBUS-TBNA cytological sampling is routinely performed for pathological diagnosis, mediastinal staging, and molecular testing in lung cancer patients. EBUS-TBNA samples are not formally accepted for testing programmed death-ligand 1 (PD-L1)
Autor:
Domenico Amoroso, Alessandro Bertolini, Maria Rita Migliorino, Andrea Luciani, Adolfo Favaretto, Alba A. Brandes, Paolo Bidoli, Giuseppe Tonini, Cesare Gridelli, Filippo de Marinis
Publikováno v:
Anticancer Research. 37:2457-2464
Background/aim The management of elderly patients with advanced non-squamous NSCLC includes several strategies. Patients and methods Patients (≥70 years) were randomly assigned to bevacizumab (7.5 mg/kg i.v. on day 1) plus gemcitabine (1,200 mg/m2
Autor:
Silvia Novello, Françoise Mornex, Rafal Dziadiuszko, Martin Früh, Enriqueta Felip, Federico Cappuzzo, Markus Glatzer, Corinne Faivre-Finn, Fiona H Blackhall, Ben J. Slotman, Mary O’ Brien, Dirk De Ruysscher, Esther G.C. Troost, Paul Van Houtte, Stéphanie Peeters, José Belderbos, Benjamin Besse, Sara Ramella, Fiona McDonald, Paul Martin Putora, Martin Reck, Pilar Garrido, Cécile Le Péchoux, Filippo de Marinis, Virginie Westeel, Ursula Nestle, Raffaele Califano, Joachim Widder, Christoph Pöttgen, L. Arés
Publikováno v:
Radiotherapy and Oncology, 135, 74-77. Elsevier Ireland Ltd
Radiotherapy and Oncology 135(2019), 74-77
Putora, P M, Glatzer, M, de Ruysscher, D, Faivre-Finn, C, Belderbos, J, Besse, B, Blackhall, F, Califano, R, Cappuzzo, F, de Marinis, F, Dziadiuszko, R, Felip, E, Früh, M, Garrido, P, le Pechoux, C, McDonald, F, Nestle, U, Novello, S, Brien, M O, Paz Ares, L, Peeters, S, Pöttgen, S, Ramella, S, Reck, M, Troost, E G C, van Houtte, P, Westeel, V, Widder, J, Mornex, F & Slotman, B J 2019, ' Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts ', Radiotherapy and Oncology, vol. 135, pp. 74-77 . https://doi.org/10.1016/j.radonc.2019.02.010
Radiotherapy and Oncology 135(2019), 74-77
Putora, P M, Glatzer, M, de Ruysscher, D, Faivre-Finn, C, Belderbos, J, Besse, B, Blackhall, F, Califano, R, Cappuzzo, F, de Marinis, F, Dziadiuszko, R, Felip, E, Früh, M, Garrido, P, le Pechoux, C, McDonald, F, Nestle, U, Novello, S, Brien, M O, Paz Ares, L, Peeters, S, Pöttgen, S, Ramella, S, Reck, M, Troost, E G C, van Houtte, P, Westeel, V, Widder, J, Mornex, F & Slotman, B J 2019, ' Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts ', Radiotherapy and Oncology, vol. 135, pp. 74-77 . https://doi.org/10.1016/j.radonc.2019.02.010
Background: The role of consolidative thoracic radiotherapy (TRT) in stage IV small cell lung cancer (SCLC) is not uniformly accepted.Methods: We obtained a list of 13 European medical oncologists from the International Association for the Study of L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9e8d893418515be78de97bf8a595780
http://hdl.handle.net/2318/1694881
http://hdl.handle.net/2318/1694881